Aptamer Group inks Optimer licensing agreement with Alphazyme

(Sharecast News) - Synthetic binders developer Aptamer Group has signed a licensing agreement with Alphazyme for the use of an Optimer binder in hot‑start PCR applications. Under the deal, Aptamer will grant Alphazyme a non‑exclusive licence to use the enzyme‑modulating Optimer across its hot‑start PCR and NGS products and services. Alphazyme will receive worldwide rights, with the agreement including royalties, milestone payments and a supply arrangement under which Aptamer will manufacture the Optimer, providing additional revenue and supply‑chain assurance.

The two companies originally entered a development agreement in June 2024, with the final Optimer delivered in December. Alphazyme's internal testing showed temperature‑sensitive control of exonuclease and polymerase activity, with the Optimer achieving functionality that typically requires two antibodies, offering both performance and cost benefits.

Aptamer added that a second Optimer development programme with Alphazyme has now completed its development phase, with candidate molecules delivered for testing and early results described as positive.

As of 1100 GMT, Aptamer shares were up 4.79% 0.84p.









Reporting by Iain Gilbert at Sharecast.com